Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Open accessPublished version of a preprint
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals. CMA promotes mitochondrial fatty acid uptake from the cytosol, facilitates fatty acid oxidation in the mitochondria, and alleviates oxidative stress. Methods: Here, we designed a randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD patients. One-dose CMA included 12.35 g L -serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl- L -cysteine (12.75%), and 3.73 g L -carnitine tartrate (18.65%). AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84. The primary endpoint was the difference in the cognitive function and daily living activity scores between the placebo and the treatment arms. The secondary aim of this study was to evaluate the safety and tolerability of CMA. A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efficacy of the CMA in AD patients. Results: We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 ( P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline ( P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment. Conclusion: Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis. Trial registration ClinicalTrials.gov NCT04044131 Registered 17 July 2019, https://clinicaltrials.gov/ct2/show/NCT04044131
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 CMA improves ADAS-Cog scores and clinical parameters. a Study design for testing the effects of CMA in AD patients. b Differences in ADAS-Cog scores in the CMA and placebo groups on days 0, 28 and 84. The ADAS-Cog scores were further analysed by stratifying the patients into high- (score > 20) and low-ADAS-Cog score (≤ 20) groups. The ADAS-Cog score was significantly decreased on day 28 vs day 0 (Log2FoldChange [FC] = − 0.33, 26% improvement, P = 0.0000003) and on day 84 vs day 0 (Log2FC = − 0.37, 29% improvement, P = 0.00001) in the CMA group. A slight but significant decrease was found in the placebo group on day 28 vs day 0 (Log2FC = − 0.16, 12% improvement, P = 0.009) and on day 84 vs day 0 (Log2FC = −0.19, 14% improvement, P = 0.001). In addition, the ADAS-Cog score was significantly decreased on day 28 vs day 0 (Log2FC = − 0.31, 24% improvement, P = 0.002) and on day 84 vs day 0 (Log2FC = − 0.38, 30% improvement, P = 0.003) in the high-score CMA group, while no significance difference was seen in the high-score placebo group. c We selected 10 patients from the severe (ADAS-COG score > 20) CMA group with matched ADAS-COG values to the placebo group (P-value: 0.693) and presented the ADAS-Cog scores. We recalculated the differences in ADAS-COG scores and found significant improvement in the CMA group whereas there was no significant difference in the placebo group. d Heatmaps showing log2FC-based alterations of the clinical variables before vs after treatment in both CMA and placebo groups. Asterisks indicate statistical significance based on Student’s t-test (P < 0.05)](https://figures.cochat.ai/paper-figures/7ee91d2488124558951cc349367da82d/combined-metabolic-activators-improve-cognitive-functions-in-alzheimers-disease-figure-1.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a phase 2 clinical trial in which a combination of metabolic activators (L-serine, N-acetyl cysteine, nicotinamide riboside, and L-carnitine tartrate) was used reported improved AD-related metabolic parameters and an approximately 20% increase in cognitive performance, although these benefits were not observed during the follow-up period.526”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [526]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Türkez, H., Altay, Ö., Yıldırım, S., Li, X., Yang, H., Bayram, C., Bolat, İ., Öner, S., Tozlu, Ö. Ö., Arslan, M. E., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121325 · Cited by 10
Self-citationRetractedCortical Surface-Based Analysis
Dale, A. M., Fischl, B., & Sereno, M. I. (1999) · NeuroImage · doi:10.1006/nimg.1998.0395 · Cited by 10,910
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237
Multi-omics approaches to disease
Hasin, Y., Seldin, M., & Lusis, A. (2017) · Genome Biology · doi:10.1186/s13059-017-1215-1 · Cited by 2,953
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Within-subject template estimation for unbiased longitudinal image analysis
Reuter, M., Schmansky, N. J., Rosas, H. D., & Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.084 · Cited by 2,356
Fang, E. F., Hou, Y., Palikaras, K., Adriaanse, B. A., Kerr, J. S., Yang, B., Lautrup, S., Hasan-Olive, M. M., Caponio, D., Dan, X., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0332-9 · Cited by 1,740 · cited 2×
“Also, recent human studies suggested that the impaired hippocampal mitophagy in AD patients responds well to mitophagy enhancement strategies and such treatment finally improves AD-related tau pathologies in human neuronal cells and memory deficits in transgenic models [23].”
BackgroundBrain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Research works printed but not linked: 3
- Turkez H, Altay O, Yildirim S, Li X, Yang H, Bayram C, et al. Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases. Life Sci. 2023;InPress. · DOI
- Hou Y, Wei Y, Lautrup S, Yang B, Wang Y, Cordonnier S, et al. NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS-STING. Proc Natl Acad Sci U S A. 2021;118(37): e2011226118. · DOI · Paper page
- Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, et al. NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018;115(8):E1876–85. · DOI · Paper page
Cited by
Roles of Oxidative Stress in Synaptic Dysfunction and Neuronal Cell Death in Alzheimer’s Disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Antioxidants · doi:10.3390/antiox12081628 · Cited by 188
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Pathological mechanisms and treatment progression of Alzheimer’s disease
Zhang, J., Kong, G., Yang, J., Pang, L., & Li, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02886-9 · Cited by 300
Self-citationWhat is really known about the effects of nicotinamide riboside supplementation in humans
Damgaard, M. V., & Treebak, J. T. (2023) · Science Advances · doi:10.1126/sciadv.adi4862 · Cited by 111
Chen, Y., Li, Y., Fan, Y., Chen, S., Chen, L., Chen, Y., & Chen, Y. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2302310 · Cited by 95
Metadata
- Authors
- Yulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., Nogaylar, R., Ozsimsek, A., Bayram, C., Bolat, I., Oner, S., Tozlu, O. O., Arslan, M. E., Hacimuftuoglu, A., Yildirim, S., Arif, M., Shoaie, S., Zhang, C., Nielsen, J., Turkez, H., Borén, J., Uhlén, M., & Mardinoglu, A.
- Affiliations
- King's College London (GB)
- Science for Life Laboratory (SE)
- Alanya Alaaddin Keykubat Üniversitesi (TR)
- Atatürk University (TR)
- Erzurum Technical University (TR)
- Chalmers University of Technology (SE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Uhlén, Mathias
- ORCID
- Venue
- Translational Neurodegeneration
- Published
- 2023-01-26
- Volume
- 12
- Issue
- 1
- Pages
- 4-4
- ISSN
- 2047-9158 (ISSN-L)
- PMC
- PMC9879258
- OpenAlex
- W4318195490
- Cited by
- 79
- References
- 150
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 24 · 2023: 15
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Translational Neurodegeneration (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Alanya Alaaddin Keykubat University Institutional Repository (submittedVersion, cc-by-nc-nd)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Chalmers Research (Chalmers University of Technology) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Knut och Alice Wallenbergs Stiftelse (72110)
- Royal Institute of Technology
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- Alzheimer's disease, cognitive function, L-serine, nicotinamide riboside, N-acetylcysteine, mitochondrial fatty acid oxidation, oxidative stress, NAD+ metabolism, glutathione metabolism, plasma metabolome, plasma proteome, hippocampal volume, cortical thickness
- MeSH terms
- Alzheimer Disease, Animals, Cognition, Double-Blind Method, Humans, Treatment Outcome, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. https://app.cochat.ai/papers/10.1186/s40035-023-00336-2
- The paper
- Yulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., Nogaylar, R., Ozsimsek, A., Bayram, C., Bolat, I., Oner, S., Tozlu, O. O., Arslan, M. E., Hacimuftuoglu, A., Yildirim, S., . . . Mardinoglu, A. (2023). Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Translational Neurodegeneration. https://doi.org/10.1186/s40035-023-00336-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.